Back to top
more

Zoetis (ZTS)

(Real Time Quote from BATS)

$173.89 USD

173.89
2,384,087

+3.52 (2.07%)

Updated Nov 7, 2024 03:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?

by Zacks Equity Research

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases second-quarter 2021 results.

Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

by Ekta Bagri

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

CORT or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CORT vs. ZTS: Which Stock Is the Better Value Option?

Why Zoetis (ZTS) Could Beat Earnings Estimates Again

by Zacks Equity Research

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FTCS

Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study

by Zacks Equity Research

Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.

AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe

by Zacks Equity Research

AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.

TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study

by Zacks Equity Research

TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study

by Zacks Equity Research

Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.

Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral

by Zacks Equity Research

Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.

AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AMRX vs. ZTS: Which Stock Is the Better Value Option?

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.

Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck

by Zacks Equity Research

Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.

Riya Anand headshot

Pandemic Boosts Animal Health Spending: 4 Stocks to Buy

by Riya Anand

Stocks like PetIQ (PETQ), IDEXX Laboratories (IDXX), Phibro Animal Health (PAHC) and Zoetis (ZTS) offering animal health products and services make great picks for long term.

Novo Nordisk (NVO) Inks Deal to Develop Heart Failure Treatment

by Zacks Equity Research

Novo Nordisk (NVO) inks an exclusive license agreement with Heartseed Inc. to manufacture and commercialize the latter's HS-001, a cell therapy developed for the treatment of heart failure.

Omeros (OMER) Announces Data on Narsoplimab in COVID-19 Patients

by Zacks Equity Research

Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

by Zacks Equity Research

Verrica's (VRCA) NDA for lead candidate, VP-102, a drug-device combination treatment for skin disease, molluscum, is under review. FDA delays decision on potential approval for the candidate by three months.

Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod

by Zacks Equity Research

The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.

Viatris (VTRS) Beats on Q1 Earnings & Sales, Announces Dividend

by Zacks Equity Research

Viatris (VTRS) beats on Q1 earnings while sales surpass expectations. The company announces inaugural quarterly dividend.

AMRX or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AMRX vs. ZTS: Which Stock Is the Better Value Option?